Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Meridia Pediatric Adverse Events Will Get Continued Monitoring

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA notes that only one pediatric adverse case report was recorded and additional surveillance is necessary for a more meaningful analysis.

You may also be interested in...

Sparlon Shows 31 Cases Of Suicidality, Aggression or Psychosis In ADHD Database

Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.

Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says

Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts